CLINICAL_TRIALS
trial_result
· 2020-01-21
Clinical Trial Update: Linagliptin Add-on to Insulin Background Therapy [Phase 3]
Summary
Phase 3 trial evaluating linagliptin added to insulin background therapy in type 2 diabetes; results completed with posted data.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Boehringer Ingelheim | Conditions: Diabetes Mellitus, Type 2 | Phase 3 | Status: COMPLETED | Results posted: 2020-01-21